U.S., Jan. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07338838) titled 'To Evaluate the Tolerability and Pharmacokinetics of TQB3142 for Injection in Patients With Advanced Malignant Tumors' on Jan. 04.
Brief Summary: To explore the safety, tolerability and pharmacokinetics of TQB3142 for injection in subjects with advanced malignant tumors
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Advanced Malignant Tumors
Intervention:
DRUG: TQB3142 injection
TQB3142 for injection is a B-cell lymphoma-extra large inhibitor.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Published by HT Digital Content Services with permission from Hea...